申请人:SCHERING CORPORATION
公开号:EP1777223A1
公开(公告)日:2007-04-25
Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are the uses of the compounds of formula I for treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion). Also disclosed are uses of the compounds of formula I in combination with a H1 receptor antagonist for treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion).
公开了式 I 的新型化合物,其中 M1 是 CH 或 N,M2 是 C(R3) 或 N;R1 是任选取代的吲哚基或其氮杂衍生物;R2 是任选取代的芳基或杂芳基;其余变量如说明书中所定义。还公开了包含式 I 化合物的药物组合物。还公开了式 I 化合物用于治疗各种疾病或病症的用途,例如过敏、过敏引起的气道反应和鼻塞(如鼻塞)。还公开了式 I 化合物与 H1 受体拮抗剂结合用于治疗各种疾病或病症的用途,例如过敏、过敏引起的气道反应和充血(如鼻塞)。